VTRS Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of -93.48% compared to Viatris's net margin of 21.68%. Viatris's return on equity of -20.24% beat Eli Lilly and's return on equity of 78.25%.

Viatris has a consensus price target of $11.6043, signalling upside risk potential of 39.98%. On the other hand Eli Lilly and has an analysts' consensus of $955.31 which suggests that it could grow by 33.85%. Given that Viatris has higher upside potential than Eli Lilly and, analysts believe Viatris is more attractive than Eli Lilly and.

Viatris has a beta of 0.887, which suggesting that the stock is 11.265% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.104%.

Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 5.79%. Eli Lilly and offers a yield of 0.79% to investors and pays a quarterly dividend of $1.50 per share. Viatris pays -90.63% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Viatris quarterly revenues are $3.3B, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Viatris's net income of -$3B is lower than Eli Lilly and's net income of $2.8B. Notably, Viatris's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 58.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 0.69x versus 13.15x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of -93.48% compared to Viatris's net margin of 32.71%. Viatris's return on equity of -20.24% beat Merck &'s return on equity of 39.02%.

Viatris has a consensus price target of $11.6043, signalling upside risk potential of 39.98%. On the other hand Merck & has an analysts' consensus of $101.91 which suggests that it could grow by 31.36%. Given that Viatris has higher upside potential than Merck &, analysts believe Viatris is more attractive than Merck &.

Viatris has a beta of 0.887, which suggesting that the stock is 11.265% less volatile than S&P 500. In comparison Merck & has a beta of 0.429, suggesting its less volatile than the S&P 500 by 57.139%.

Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 5.79%. Merck & offers a yield of 4.07% to investors and pays a quarterly dividend of $0.81 per share. Viatris pays -90.63% of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Viatris quarterly revenues are $3.3B, which are smaller than Merck & quarterly revenues of $15.5B. Viatris's net income of -$3B is lower than Merck &'s net income of $5.1B. Notably, Viatris's price-to-earnings ratio is -- while Merck &'s PE ratio is 11.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 0.69x versus 3.08x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -93.48% compared to Viatris's net margin of 21.63%. Viatris's return on equity of -20.24% beat Pfizer's return on equity of 8.72%.

Viatris has a consensus price target of $11.6043, signalling upside risk potential of 39.98%. On the other hand Pfizer has an analysts' consensus of $29.50 which suggests that it could grow by 26.5%. Given that Viatris has higher upside potential than Pfizer, analysts believe Viatris is more attractive than Pfizer.

Viatris has a beta of 0.887, which suggesting that the stock is 11.265% less volatile than S&P 500. In comparison Pfizer has a beta of 0.588, suggesting its less volatile than the S&P 500 by 41.208%.

Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 5.79%. Pfizer offers a yield of 7.29% to investors and pays a quarterly dividend of $0.43 per share. Viatris pays -90.63% of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Viatris quarterly revenues are $3.3B, which are smaller than Pfizer quarterly revenues of $13.7B. Viatris's net income of -$3B is lower than Pfizer's net income of $3B. Notably, Viatris's price-to-earnings ratio is -- while Pfizer's PE ratio is 16.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 0.69x versus 2.13x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Treace Medical Concepts has a net margin of -93.48% compared to Viatris's net margin of -30.29%. Viatris's return on equity of -20.24% beat Treace Medical Concepts's return on equity of -47.17%.

Viatris has a consensus price target of $11.6043, signalling upside risk potential of 39.98%. On the other hand Treace Medical Concepts has an analysts' consensus of $9.73 which suggests that it could grow by 65.45%. Given that Treace Medical Concepts has higher upside potential than Viatris, analysts believe Treace Medical Concepts is more attractive than Viatris.

Viatris has a beta of 0.887, which suggesting that the stock is 11.265% less volatile than S&P 500. In comparison Treace Medical Concepts has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Viatris has a quarterly dividend of $0.12 per share corresponding to a yield of 5.79%. Treace Medical Concepts offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viatris pays -90.63% of its earnings as a dividend. Treace Medical Concepts pays out -- of its earnings as a dividend.

Viatris quarterly revenues are $3.3B, which are larger than Treace Medical Concepts quarterly revenues of $52.6M. Viatris's net income of -$3B is lower than Treace Medical Concepts's net income of -$15.9M. Notably, Viatris's price-to-earnings ratio is -- while Treace Medical Concepts's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viatris is 0.69x versus 1.74x for Treace Medical Concepts. Usually stocks with elevated PS ratios are considered overvalued.